New combo sedation may ease scary lung scopes for kids
NCT ID NCT06755996
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of two sedatives—dexmedetomidine nasal spray and remimazolam—in 150 children aged 2-6 years undergoing bronchoscopy. The goal was to see if this approach provides safe and effective sedation. Researchers measured how quickly children reached adequate sedation and how fast they woke up afterward.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- dexmedetomidine and remimazolam
- What this could lead to
- If successful, this sedation approach could make pediatric bronchoscopy safer and more comfortable for children.
- What could go wrong
- This is a small, completed study without a control group, so results may not apply broadly. Risks include allergic reactions or side effects from the drugs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
150 people
The number who actually took part.
- Started
-
Jan 2025
- Finished
-
Aug 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
2 to 6 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 2-6 years old (24\~72 months); * ASA I-II; * sign the informed consent. Exclusion Criteria: * Severe rhinitis, nasal deformity; * abnormal liver and kidney function; * severe dehydration, severe malnutrition, hypoproteinemia or anaemia Hb \<10 g/dl; * children with neurological disease; * history of allergy to the study drug; * recent participation in other clinical studies.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Fiberoptic bronchoscopy are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tongji hospital
Wuhan, Hubei, 430030, China